Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASO Visual Abstract: Multimodal Prehabilitation and Outcomes after Gastroesophageal Cancer Surgery: A Cohort Study of Pulmonary Complications and Resilience to Major Postoperative Events.

Annals of surgical oncology·2026
Same author

Biological and Pathophysiological Mechanisms of Postoperative Complications Affecting Long-Term Survival: A Narrative Review.

Cureus·2026
Same author

Impact of geographical location on ICU outcomes in adults: a scoping review.

BMJ open·2026
Same author

Leucocytosis and outcomes in older ICU patients after ischaemic stroke: a binational multicentre cohort study.

BMJ neurology open·2026
Same author

Multi-modal Prehabilitation and Outcomes after Gastroesophageal Cancer Surgery: A Cohort Study of Pulmonary Complications and Resilience to Major Postoperative Events.

Annals of surgical oncology·2026
Same author

From Donor Liver to Recipient Pulmonary Artery: Embolization of a Transected Central Venous Catheter During Liver Transplantation, A Rare Complication of Organ Procurement.

Clinical case reports·2026

Related Experiment Video

Updated: May 13, 2026

Coronary Angiography During Ex-Situ Heart Perfusion in a Porcine Model
06:25

Coronary Angiography During Ex-Situ Heart Perfusion in a Porcine Model

Published on: July 12, 2024

Sugammadex.

Dharshi Karalapillai1, Melissa Kaufman, Laurence Weinberg

  • 1Austin Health, Melbourne, VIC, Australia. dharshi.karalapillai@austin.org.au

Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine
|February 26, 2013
PubMed
Summary

Sugammadex offers a superior method for reversing neuromuscular blockade from rocuronium and vecuronium. This review details its pharmacology, clinical use, and cost-effectiveness in intensive care settings.

Area of Science:

  • Anesthesiology and Critical Care Medicine

Background:

  • Sugammadex is a novel selective relaxant binding agent.
  • It reverses neuromuscular blockade induced by rocuronium and vecuronium.
  • Current reversal strategies have limitations in speed, efficacy, and side effect profiles.

Purpose of the Study:

  • To review the pharmacological properties of sugammadex.
  • To discuss the clinical applications of sugammadex in intensive care.
  • To evaluate the cost-effectiveness of sugammadex in intensive care practice.

Main Methods:

  • Literature review of pharmacological features.
  • Analysis of clinical studies on sugammadex use.
  • Economic evaluation of sugammadex versus standard care.

Main Results:

More Related Videos

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
05:52

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model

Published on: November 4, 2021

Related Experiment Videos

Last Updated: May 13, 2026

Coronary Angiography During Ex-Situ Heart Perfusion in a Porcine Model
06:25

Coronary Angiography During Ex-Situ Heart Perfusion in a Porcine Model

Published on: July 12, 2024

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
05:52

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model

Published on: November 4, 2021

  • Sugammadex demonstrates rapid and effective reversal of neuromuscular blockade.
  • Its mechanism offers advantages over traditional reversal agents.
  • Evidence suggests favorable cost-effectiveness in specific intensive care scenarios.

Conclusions:

  • Sugammadex represents a significant advancement in neuromuscular blockade reversal.
  • Further guidance is needed for its optimal integration into intensive care.
  • Its use may improve patient outcomes and resource utilization in critical care.